Synthesis of the PET Tracer
Cell Line, Tumor
Chemistry Techniques, Synthetic
Drug Resistance, Neoplasm
Enzyme Activation
Extracellular Signal-Regulated MAP Kinases
/ metabolism
Humans
Iodine Radioisotopes
/ chemistry
Mitogen-Activated Protein Kinases
/ metabolism
Positron-Emission Tomography
Pyridones
/ chemical synthesis
Pyrimidinones
/ chemical synthesis
Radioactive Tracers
MEK
melanoma
oncology
radiochemistry
small-molecular inhibitor
trametinib
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
01
2020
accepted:
16
04
2020
pubmed:
24
5
2020
medline:
6
3
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
Trametinib is an extremely potent allosteric inhibitor of mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) (MEK) 1/2, which has been approved for treatment of metastatic melanoma and anaplastic thyroid cancer in patients with confirmed BRAF
Identifiants
pubmed: 32444378
pii: jnumed.120.241901
doi: 10.2967/jnumed.120.241901
pmc: PMC9364901
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine-124
0
Pyridones
0
Pyrimidinones
0
Radioactive Tracers
0
trametinib
33E86K87QN
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1845-1850Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215700
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243895
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA062948
Pays : United States
Informations de copyright
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Références
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Science. 2018 Dec 21;362(6421):1416-1422
pubmed: 30573629
Onco Targets Ther. 2015 Aug 25;8:2251-9
pubmed: 26347206
Chem Commun (Camb). 2016 Nov 3;52(90):13277-13280
pubmed: 27775106
Org Lett. 2018 Apr 6;20(7):1752-1755
pubmed: 29561158
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nature. 2016 Jun 30;534(7609):647-51
pubmed: 27338794
Cell. 2017 Feb 23;168(5):817-829.e15
pubmed: 28215705
PLoS One. 2017 Jun 19;12(6):e0179936
pubmed: 28628649
J Nucl Med. 2018 Feb;59(2):210-215
pubmed: 28912145
Biochem J. 2000 Oct 15;351 Pt 2:289-305
pubmed: 11023813
Pharmacol Res. 2017 Mar;117:20-31
pubmed: 27956260
Clin Cancer Res. 2011 Mar 1;17(5):989-1000
pubmed: 21245089
Oncogene. 2004 Mar 25;23(13):2347-56
pubmed: 14743208
Cancer Discov. 2011 Jun;1(1):35-43
pubmed: 22140652
Chem Rev. 1999 Dec 8;99(12):3421-3434
pubmed: 11849026
Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7
pubmed: 11584300
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889